Biofrontera Inc. (BFRI) Stock Analysis

Company Overview

Biofrontera Inc. (BFRI) is capitalised at $23.91M on the latest close. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. Headcount on file is 84.

BFRI last closed at $1.61 on September 4, 2026. That is +$0.10 (+6.62%) against the previous close. The 52-week range on file runs from $0.56 to $1.63. The latest close sits 190.09% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $41.71M. Against the prior fiscal year total of $37.32M, that is a change of +11.75%. The same year closed with a net loss of $10.54M. The reported profit margin is −13.79%. That is 10.6 percentage points below the Drug Manufacturers - Specialty & Generic median of −3.14%. Earnings per share on a trailing basis come to −0.46.

Across the 4 fiscal years on file, revenue moves from $28.67M in 2022 to $41.71M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The forward P/E on file is 3.74. Measured against sales, the shares trade at 0.52 times revenue. On price-to-sales that is 0.2 times the Drug Manufacturers - Specialty & Generic median of 2.3. The medians here are taken across 103 Drug Manufacturers - Specialty & Generic companies that report the metric.

The reported beta is 0.84. Annualized volatility over the trailing 4 years is 101.85%. Over the trailing twelve months the price has returned +91.90%. Measured over 3 years, that is −42.64% a year compounded.

Growth & Income

The record shows no dividend for BFRI.

2026 is still running; the price is +182.46% year to date. Across the complete calendar years on file, 2025 returned −47.71% and 2022 returned −87.81%. Of the 4 complete calendar years on file, 0 finished higher.